Hernia Surgery Clinical Trial
— CB1ROfficial title:
Use of Biopsies of Abdominal Subcutaneous Fat to Study the Role of the Activation of Endocannabinoid 1 Receptors (CB1R) on Adipocyte Glucolipid Metabolism
| Verified date | February 2024 |
| Source | Centre Hospitalier Universitaire Dijon |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Obesity is associated with hyperactivation of the endocannabinoid system, and its inhibition by the administration of CB1 receptor (CB1R) antagonists, leads to a decrease in food intake, weight loss and an improvement in metabolic parameters. Even though the reduction in food intake following central CB1R inactivation seems to be the principal cause of weight loss and the improvement in metabolic parameters, several studies in animals and humans have indicated that peripheral CB1R could also be implicated in the regulation of glucolipid metabolism. As a result, it has been suggested that the long-term beneficial effects of inactivation of the endocannabinoid system are due to both central effects on food intake and peripheral effects involving adipose tissue, the liver, skeletal muscle and the pancreas. It appears essential to determine the role of CB1R located in peripheral tissues and in particular in adipose tissue, which plays an active role in maintaining glucolipid homeostasis. The experiments conducted in this project consist in studying in biopsies of abdominal subcutaneous fat whether activation of adipocyte CB1R modifies adipocyte metabolism by determining the mechanisms. The investigators hypothesize that activation of CB1R in adipose tissue will lead to the stimulation of lipolysis dependent on the alteration of the insulin signal, and therefore that inactivation of the endocannabinoid system by blocking peripheral CB1R could constitute a therapeutic approach to improve obesity-related insulin resistance and dyslipidaemia.
| Status | Completed |
| Enrollment | 51 |
| Est. completion date | January 7, 2020 |
| Est. primary completion date | January 7, 2020 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 18 Years to 70 Years |
| Eligibility | healthy subjects Inclusion Criteria: - men aged 18 to 70 years - persons who have provided oral consent - persons undergoing surgery for hernia Exclusion Criteria: - persons without health insurance cover - BMI > 30 - diabetes - associated diseases: cancer, chronic inflammatory diseases - adults under guardianship obese subjects Inclusion Criteria: - men aged 18 to 70 years - BMI > 30 - persons who have provided oral consent - persons undergoing surgery for hernia Exclusion Criteria: - persons without health insurance cover - diabetes - associated diseases: cancer, chronic inflammatory diseases - adults under guardianship diabetic obese subjects Inclusion Criteria: - men aged 18 to 70 years - type 2 diabetic not treated with Insulin or GLP-1 agonist - BMI > 30 - persons who have provided oral consent - persons undergoing surgery for hernia Exclusion Criteria: - persons without health insurance cover - associated diseases: cancer, chronic inflammatory diseases - adults under guardianship |
| Country | Name | City | State |
|---|---|---|---|
| France | CHU Dijon Bourgogne | Dijon |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Universitaire Dijon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Glucolipid metabolism analysis in human abdominal subcutaneous and visceral fat | Baseline |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04595877 -
Double-blind, Randomized Controlled Study to Assess the Analgesic Effect of 2 g of Magnesium Dipyrone (Metamizol) and Changes in Plasma Beta-endorphin Immunoreactivity Values in Patients Undergoing Elective Inguinal Herniorrhaphy Under Epidural Anesthesia.
|
Phase 4 |